Carroll Investors’s Exact Sciences EXAS Stock Holding History

Carroll Investors’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-576	Closed	-$44K	–	181
2021 Q4	$44K	Buy	+576	New	+$50.8K	0.03%	102

Other funds holding EXAS

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Carroll Investors's EXAS Position: Q1 2022 in Review

Carroll Investors sold out of Exact Sciences (EXAS) in Q1 2022, closing a stake of 576 shares — an estimated $44K sold.

Carroll Investors first reported a position in EXAS in Q4 2021 and held it in 1 quarter. The position peaked at $44K in Q4 2021. 559 funds tracked by Wall St. Rank hold EXAS as of Q1 2022.

Carroll Investors reported no remaining Exact Sciences position as of Q1 2022 after selling out during the quarter.
Carroll Investors sold 576 Exact Sciences shares in Q1 2022, an estimated $44K.
Carroll Investors first reported a position in Exact Sciences in Q4 2021 and held it in 1 quarter.
Carroll Investors's Exact Sciences position peaked at $44K in Q4 2021.
559 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2022.

Based on Carroll Investors's 13F filing for Q1 2022, filed 28 Apr 2022.